๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Type 2 Diabetes
Clinical trial register · China

Type 2 Diabetes Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 16 Guangzhou 7 Shanghai 7 Changsha 6 Nanjing 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.5 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School3 Eli Lilly and Company2 The United Bio-Technology (Hengqin) Co., Ltd.2 Jiangsu Hansoh Pharmaceutical Co., Ltd.2
Site location
Beijing16 Guangzhou7 Shanghai7 Changsha6 Nanjing6
All 43 locations
Target enrolment
to

Type 2 Diabetes trials in China

54 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Insulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes
NCT07747402Type 2 Diabetes
DrugInsulin icodec
Xi'an International Medical Center Hospital
Phase 4
462
Xi'an
2027-01
Not yet open
Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD
NCT07778719Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsDapagliflozin·Metformin
The 95th Hospital of Putian๏ผŒPutian, Fujian, China
Not applicable
84
Putian
2026-10-01
Recruiting
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone๏ผˆUNIGUIDE-1๏ผ‰
NCT07659574Type 2 Diabetes
DrugUBT251
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 3
360
Changsha
2026-09-07
Recruiting
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ยฑ Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
NCT07653477Type 2 Diabetes
DrugSemaglutide
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 3
956
Shanghai
2026-09-07
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335Type 2 Diabetes, Cardiovascular Risk
DrugZenagamtide
Novo Nordisk A/S
Phase 3
1,778
Hefei, Beijing, Chongqing, Shenzhen, Cangzhou, Langfang, Shijiazhuang, Kaifeng
2026-08-24
Not yet open
Point-of-care Capillary HbA1c Testing for Type 2 Diabetes Screening Among At-risk Individuals in Rural Dali, China
NCT07718867Type 2 Diabetes, Pre-diabetes
The University of Hong Kong
Not applicable
720
Dali
2026-07-28
Not yet open
A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants
NCT06506175Weight Management, Type 2 Diabetes
DrugHRS9531
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
100
Qingdao
2026-07
Recruiting
Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma
NCT07722910Neovascular Glaucoma, Type 2 Diabetes
Qilu Hospital of Shandong University
Observational
98
Jinan
2026-05-23
Not yet open
Efficacy Heterogeneity of Lactobacillus Paracasei LC19 on Type 2 Diabetes
NCT07520305Type 2 Diabetes
Beijing Chao Yang Hospital
Not applicable
70
Beijing
2026-04-20
Recruiting
Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes
NCT07558863Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
The First Affiliated Hospital with Nanjing Medical University
Phase 4
60
Nanjing
2026-04-01
Not yet open
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
NCT07417306Type 2 Diabetes
DrugsHDM1005 1·HDM1005 2·Mazdutide
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
912
Beijing
2026-03-27
Active, closed
A Food-Effect Study of CX11 in Healthy Participants
NCT07349381Obesity & Overweight, Type 2 Diabetes
DrugCX11
Vincentage Pharma Co., Ltd
Phase 1
32
Shanghai
2026-03-04
Recruiting
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
NCT07394114Type 2 Diabetes
DrugsHDM1005 1·HDM1005 2
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
240
Beijing
2026-02-24
By invitation
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
NCT07456774Type 2 Diabetes
Novo Nordisk A/S
Observational
100,000
Tianjin
2026-02-13
Not yet open
Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes
NCT07063797Type 2 Diabetes, Osteoporosis, Fractures
DrugDenosumab
Peking Union Medical College Hospital
Not applicable
358
Beijing, Huai'an, Jiangxi, Kunshan
2026-02-01
Recruiting
Compilation and Preliminary Application of the Active Health Behavior Scale in Patients With Type 2 Diabetes
NCT07531459Type 2 Diabetes
Yun Ye
Observational
600
Changzhou
2025-12-24
Recruiting
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235Type 2 Diabetes
DrugIGlarLixi
Shanghai Zhongshan Hospital
Phase 4
1,316
Hefei, Huizhou, Shenzhen, Harbin, Xinxiang, Wuhan, Changsha, Hengyang
2025-12-13
Not yet open
Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes
NCT07198932Type 2 Diabetes
Yanbing Li
Observational
594
Hangzhou, Baoding, Beijing, Shanghai, Xi'an
2025-10-01
Not yet open
A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naรฏve Patients With Type 2 Diabetes
NCT07122102Type 2 Diabetes
DrugsAcarbose·Cofrogliptin
Haisco Pharmaceutical Group Co., Ltd.
Not applicable
200
Zhengzhou
2025-10-01
Not yet open
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
NCT07156500Type 2 Diabetes
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
204
Beijing
2025-09-30
Not yet open
A Phase 3 Study of HS-20094 in Patients With T2DM
NCT07156539Type 2 Diabetes
DrugDulaglutide
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
546
Jinan, Tianjin
2025-09-30
Recruiting
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
NCT07083154Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
DrugMazdutide
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3
420
Changsha, Changzhou, Nanjing, Dalian, Shanghai
2025-09-27
Recruiting
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
NCT07193459Type 2 Diabetes
DrugHDM1002
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
360
Beijing
2025-08-12
Recruiting
A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
NCT07032688Type 2 Diabetes
DrugsSHR-3167·Insulin Degludec
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
55
Chengdu
2025-08-11
Not yet open
Safety Evaluation of Pueraria Lobata Radix in Specific Consumption Scenarios for Type 2 Diabetes
NCT07079085Type 2 Diabetes
Jiangxi University of Traditional Chinese Medicine
Observational
500
Nanchang
2025-08-01
Recruiting
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
NCT07060456Type 2 Diabetes
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
300
Beijing
2025-07-25
Recruiting
Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm
NCT07066891Diabetes Mellitus, Type 2 Diabetes
Sun Yat-sen University
Not applicable
400
Guangzhou
2025-07-15
Recruiting
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
NCT07082114Type 2 Diabetes
DrugsHDM1002·Dapagliflozin
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
800
Yueyang
2025-07-14
Recruiting
Hybrid Closed-Loop for Perioperative Glycemic Control in T2DM With Parenteral Nutrition
NCT07121504Type 2 Diabetes
Second Xiangya Hospital of Central South University
Not applicable
40
Changsha
2025-06-26
Active, closed
A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
NCT07026968Type 2 Diabetes
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3
815
Shijiazhuang
2025-06-20
Recruiting
Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
NCT07374328Type 2 Diabetes
DrugsSitagliptin·Semaglutide
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2
240
Guangzhou
2025-06-01
Recruiting
Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets
NCT07023172Type 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
3,000
Xinyang, Nanjing
2025-05-30
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-19
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Not yet open
A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects
NCT06974487Type 2 Diabetes
DrugsGZR102·GZR4·GZR18
Gan & Lee Pharmaceuticals.
Phase 1
30
Beijing
2025-05-08
Recruiting
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
NCT07109700Type 2 Diabetes
DrugsHDM1005 1·HDM1005 2·Dulaglutide
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 2
216
Beijing
2025-04-30
Recruiting
Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial
NCT06863532Type 2 Diabetes
DrugsSGLT2i·Cofrogliptin·Metformin
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
80
Hangzhou
2025-03-30
Recruiting
Metformin Hydrochloride Sustained-release Tablets (โ…ข) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease
NCT06932874Atherosclerotic Heart Disease, Type 2 Diabetes
China National Center for Cardiovascular Diseases
Phase 4
356
Beijing
2025-03-04
Not yet open
Efficacy and Safety of LC-Z300-01 in Chinese With Type 2 Diabetes
NCT06847178Diabetes, Type 2 Diabetes
Shanghai Changzheng Hospital
Phase 2/3
60
Shanghai
2025-03-01
Recruiting
Efficacy of Lactobacillus Paracasei LC19 on Type 2 Diabetes
NCT06639425Type 2 Diabetes
Beijing Chao Yang Hospital
Not applicable
60
Beijing
2024-10-12
Recruiting
Investigating the Insulin Resistance in Individuals With Type 2 Diabetes
NCT06428968Type 2 Diabetes
Central South University
Not applicable
30
Changsha
2024-09-06
Recruiting
The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy
NCT06461377Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
The First Affiliated Hospital with Nanjing Medical University
Phase 4
50
Nanjing
2024-06-13
Not yet open
LCMD for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual Differences
NCT06442150Type 2 Diabetes Mellitus in Obese, Type 2 Diabetes
Shanghai Municipal Hospital of Traditional Chinese Medicine
Not applicable
170
Shanghai
2024-06-01
Not yet open
Henagliflozin's Impact on Prediabetes Remission
NCT06448130PreDiabetes, Prediabetic State, Type 2 Diabetes, Glucose Metabolism Disorders
DrugHenagliflozin
Shandong Provincial Hospital
Phase 4
984
Chuzhou, Hefei, Fuzhou, Lanzhou, Foshan, Guangzhou, Guanzhou, Shenzhen
2024-06
Recruiting
Characteristics of Papez Loop Neural Network in T2DM ๏ผˆType 2 Diabetes Mellitus๏ผ‰
NCT06912321Type 2 Diabetes, Insulin Resistance, Cognitive Impairment
Nanjing First Hospital, Nanjing Medical University
Observational
400
Nanjing
2024-05-01
Not yet open
Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus
NCT06085378Acute Ischemic Stroke, Type 2 Diabetes
DrugUrinary kallidinogenase
First Affiliated Hospital, Sun Yat-Sen University
Not applicable
630
Guangzhou
2024-01-01
Recruiting
Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus
NCT06727721Diabetes, Type 2 Diabetes
Lu jin ๏ผŒMD
Phase 2
10
Shanghai
2023-11-06
Active, closed
Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes
NCT07003191Type 2 Diabetes
Sun Yat-sen University
Observational
2,600
Guangzhou
2023-08-02
Recruiting
The PRECISION-T2D Study: Precision Nutrition Study for Type 2 Diabetes
NCT05885828Type 2 Diabetes
Westlake University
Not applicable
200
Hangzhou
2023-07-17
Recruiting
Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community
NCT05349955Type 2 Diabetes, Cardiovascular Complication, Diabetic Kidney Disease
Shanghai Zhongshan Hospital
Not applicable
5,600
Suzhou
2022-11-21
Recruiting
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
NCT05888909Diabetic Nephropathy Type 2, Diabetic Kidney Disease, Type 2 Diabetes
Chinese PLA General Hospital
Observational
2,000
Beijing
2022-08-01
Recruiting
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease
NCT05439226Type 2 Diabetes
State Key Laboratory of Subhealth Intervention Technology
Not applicable
120
Yichang, Changsha
2022-07-05
Recruiting
Coronary Artery Calcification in Type 2 Diabetes Mellitus (USCAC Study)
NCT04889053Type 2 Diabetes, Vascular Calcification, Coronary Artery Calcification, Strains
University of South China
Observational
1,400
Hengyang
2021-06-01
Recruiting
China Diabetes Cognitive Dysfunction Early Diagnosis and Intervention Study (China-DECODE Study)
NCT06650969Type 2 Diabetes, Subjective Cognitive Decline, Mild Cognitive Impairment, Dementia
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
10,000
Nanjing
2016-10-01
Rows per page Showing 1–54 of 54
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/type-2-diabetes

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 54 of those studies listing the condition Type 2 Diabetes.

How many Type 2 Diabetes trials are recruiting in China?

31 of the 54 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 17 have not yet opened recruitment, 5 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Type 2 Diabetes), 54 studies
PhaseStudiesRecruitingShare
Not applicable15827.8%
Phase 314825.9%
Observational11720.4%
Phase 46411.1%
Phase 1417.4%
Phase 2223.7%
Phase 1/2111.9%
Phase 2/3101.9%

Most active sponsors

Lead sponsors with the most studies (Type 2 Diabetes)
Lead sponsorStudiesRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.54
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School33
Beijing Chao Yang Hospital21
Eli Lilly and Company20
Fujian Shengdi Pharmaceutical Co., Ltd.21
Jiangsu Hansoh Pharmaceutical Co., Ltd.20
Novo Nordisk A/S21
Shanghai Zhongshan Hospital22
Sun Yat-sen University21
The First Affiliated Hospital with Nanjing Medical University22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.